{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:10:46Z","timestamp":1778785846065,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["U10CA180886"],"award-info":[{"award-number":["U10CA180886"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["U10CA180899"],"award-info":[{"award-number":["U10CA180899"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK\/02\/014"],"award-info":[{"award-number":["CRUK\/02\/014"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01GM0869"],"award-info":[{"award-number":["01GM0869"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["BMBF\/Era-Net 01KT1310"],"award-info":[{"award-number":["BMBF\/Era-Net 01KT1310"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70\\u20132551-Jue3"],"award-info":[{"award-number":["70\\u20132551-Jue3"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["108128"],"award-info":[{"award-number":["108128"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114229","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T15:32:21Z","timestamp":1721057541000},"page":"114229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials"],"prefix":"10.1016","volume":"208","author":[{"given":"Xavier","family":"Choderlos de Laclos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Risbourg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Bertucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Janeway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Juergens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"C\u00e9cile Le Deley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Marec-B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Ranft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Dominique","family":"Tabone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael","family":"Windsor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Dirksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Gandemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114229_bib1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/his.14265","article-title":"Updates from the 2020 World Health Organization classification of soft tissue and bone tumours","volume":"78","author":"Anderson","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.ejca.2024.114229_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27251","article-title":"Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma","volume":"65","author":"Worch","year":"2018","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2024.114229_bib3","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.21.00358","article-title":"Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children\u2019s Oncology Group Report","volume":"39","author":"Leavey","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib4","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1002\/cncr.25840","article-title":"Clinical features and outcomes in patients with extraskeletal ewing sarcoma","volume":"117","author":"Applebaum","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114229_bib5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","article-title":"Survival of European adolescents and young adults diagnosed with cancer in 2000\u201307: population-based data from EUROCARE-5","volume":"17","author":"Trama","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114229_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.23.01367","article-title":"Survival Trends Among Adolescents and Young Adults Diagnosed With Cancer in the United States: Comparisons With Children and Older Adults","volume":"42","author":"Keegan","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib7","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2018.78.2516","article-title":"High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008","volume":"36","author":"Whelan","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib8","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.19.00915","article-title":"High-dose chemotherapy compared with standard chemotherapy and lung radiation in ewing sarcoma with pulmonary metastases: results of the European Ewing tumour working initiative of national groups, 99 Trial and EWING 2008","volume":"37","author":"Dirksen","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib9","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 Trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.soncn.2015.05.003","article-title":"Toxicity of Cancer Therapy In Adolescents And Young Adults (AYAs)","volume":"31","author":"Bukowinski","year":"2015","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.ejca.2024.114229_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/pbc.20820","article-title":"Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial","volume":"47","author":"Juergens","year":"2006","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2024.114229_bib12","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ejca.2015.06.123","article-title":"Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial","volume":"51","author":"van den Berg","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114229_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/MOH.0b013e328364f573","article-title":"Hematopoietic stem cell transplantation activity in Europe","volume":"20","author":"Gratwohl","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.ejca.2024.114229_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00066-009-1009-9","article-title":"Radiation toxicity following busulfan\/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: Review of GPOH Data","volume":"185","author":"B\u00f6lling","year":"2009","journal-title":"Strahl Onkol"},{"key":"10.1016\/j.ejca.2024.114229_bib15","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1200\/JCO.21.01942","article-title":"High-dose treosulfan and melphalan as consolidation therapy versus standard therapy for high-risk (Metastatic) Ewing Sarcoma","volume":"40","author":"Koch","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/annonc\/mdu153","article-title":"ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas","volume":"25","author":"Wilhelm","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.114229_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","article-title":"Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Piperno-Neumann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114229_bib18","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114229_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-023-01943-3","article-title":"Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey","volume":"58","author":"Passweg","year":"2023","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.ejca.2024.114229_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114229_bib21","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4065\/83.10.1131","article-title":"Autologous Stem Cell Transplant in 716 Patients With Multiple Myeloma: Low Treatment-Related Mortality, Feasibility of Outpatient Transplant, and Effect of a Multidisciplinary Quality Initiative","volume":"83","author":"Gertz","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2024.114229_bib22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114229_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1634\/theoncologist.2019-0532","article-title":"Feasibility of Treating Adults with Ewing or Ewing\u2010Like Sarcoma with Interval\u2010Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide","volume":"25","author":"Lu","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2024.114229_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13063-019-4026-8","article-title":"International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours \u2013 EURO EWING 2012 Protocol","volume":"21","author":"Anderton","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ejca.2024.114229_bib25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(22)01790-1","article-title":"Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial","volume":"400","author":"Brennan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114229_bib26","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.22.01815","article-title":"Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children\u2019s Oncology Group","volume":"41","author":"DuBois","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2024.114229_bib27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1159\/000165361","article-title":"Ewing\u2019s Tumors over the Age of 40 \u2013 a Retrospective Analysis of 47 Patients Treated According to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99","volume":"31","author":"Pieper","year":"2008","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejca.2024.114229_bib28","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/ijc.34326","article-title":"Late toxicity comparison of alkylating\u2010based maintenance regimen with cyclophosphamide ( VAC) vs ifosfamide ( VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro\u2010EWING99\u2013R1 in France","volume":"152","author":"Corvest","year":"2023","journal-title":"Int J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:23:24Z","timestamp":1778783004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":28,"alternative-id":["S0959804924008852"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114229","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114229"}}